ENDRA Life Sciences Inc.
NDRA· Nasdaq
NDRAENDRA Life Sciences Inc.
Filed Aug 14, 2024 · 10-Q · 45 days after period end · 0001654954-24-010642
| Metric | Q2 2024 | Q2 2023 | Q2 2022 | Q2 2021 |
|---|---|---|---|---|
| Net Income | -$2.23M | -$2.56M | -$3.59M | -$3.20M |
| EPS Diluted | — | — | — | -$0.08 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
ENDRA Life Sciences Inc. · CIK 1681682 · Engraved from SEC EDGAR
ended Jun 30, 2024 · filed Aug 14, 2024 · 45 d after period end
